Welcome to The Ammon-Pinizzotto Center for Women’s Mental Health at MGH. Our Center, established in 1989, has been renamed following the generous gift from Carol Ammon and Dr. Marie Pinizzotto. These resources will be used to realize the overarching mission of the Center.
This website provides a range of current information including discussion of new research findings in women’s mental health and how such investigations inform day-to-day clinical practice. Despite the growing number of studies being conducted in women’s health, the clinical implications of such work are frequently controversial, leaving patients with questions regarding the most appropriate path to follow. Providing these resources to patients and their doctors so that individual clinical decisions can be made in a thoughtful and collaborative fashion dovetails with the mission of our Center.
All pregnant women between the ages of 18-45 with a history of psychiatric illness are eligible to enroll in the registry. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics and antidepressants during pregnancy. We are currently seeking both controls and those being treated with atypical antipsychotics and/ or antidepressants. For more information, please visit this page, call 1-866-961-2388 or e-mail firstname.lastname@example.org.
Course of ADHD in Pregnancy and the Postpartum
If you are less than 20 weeks pregnant and have a history of ADHD, you may be eligible to take part in an observational research study for women maintaining, decreasing, or discontinuing psychostimulants during pregnancy and the postpartum. Women who participate will have 6 study visits that can be completed in-person at Massachusetts General Hospital or over the phone.
For more information, please call (617)726-2912 or email the study coordinator at email@example.com
Are you pregnant or planning a pregnancy? Do you feel depressed or have a history of depression? If you are less than 28 weeks pregnant or trying to conceive and have experienced depression now or in the past, you may be eligible to take part in a research study for the treatment of depression with a prenatal supplement. For more information, please visit this page, call Taylor at 617-643-9284 or email firstname.lastname@example.org
Are you pregnant or planning to become pregnant? Do you have a history of depression? Do you want to lose weight or have a healthier lifestyle? You may be eligible to participate in a research study evaluating a new lifestyle intervention for weight loss. Participants will receive 10 sessions of therapy at no cost to you.
If you are interested in participating or would like additional information, please call Samantha at 617-643-2076.
The MGH Center for Women’s Mental Health
Perinatal and Reproductive Psychiatry Program
Simches Research Building
185 Cambridge St Suite 2200
Boston, MA 02114
To make an appointment:
Massachusetts General Hospital Clinical Program: (617) 724-7792
Location of appointments:
Wang Ambulatory Care Center, Massachusetts General Hospital
15 Parkman St., Floor 8
Boston, MA 02114-3117
April 17, 2018
There have long been concerns regarding the use of the anticonvulsant valproate (Depakote) during pregnancy. First trimester use of valproate has been associated with a 3-5% risk of neural tube defects, as well as an increased risk of other malformations affecting the heart, limbs, and genitals. Prenatal exposure to valproate may also result in lower ...Read more
April 11, 2018
The title of the following article did not grab my attention; however, I discovered that this study, entitled Accuracy of the Whooley questions and the Edinburgh Postnatal Depression Scale in identifying depression and other mental disorders in early pregnancy published in the British Journal of Psychiatry, has some incredibly important findings. First of all, this is ...Read more
April 10, 2018
Serotonin reuptake inhibitor (SRI) antidepressants may affect platelet aggregation and thus may increase the risk of bleeding. Over the last few years, we have seen several studies which have sought to determine if exposure to SSRI antidepressants in pregnancy is associated with an increased risk of postpartum hemorrhage. The most recent study was a matched cohort ...Read more
April 4, 2018
Following the release of the MGH Perinatal Depression Scale (MGHPDS) on the App Store this past August, we are pleased to announce that the MGHPDS is now available for Android devices on the Google Play store: https://play.google.com/store/apps/details?id=org.womensmentalhealth.mghpds The MGHPDS smartphone app includes digital versions of perinatal depression screening tools including the Edinburgh Postpartum Depression Scale (EPDS) ...Read more
April 3, 2018
Multiple studies have demonstrated that the menopausal transition is associated with a 2- to 4-fold increased risk for clinically significant depressive symptoms. There have been several studies suggesting that hormone therapy may improve depressive symptoms in women presenting with depression during this transition. A recent study examined the efficacy of hormone replacement therapy in preventing the ...Read more
April 1, 2018
This week there are two very interesting articles which look at the impact of parental exposure to adverse childhood experiences may affect a child developmental outcomes. Colker and colleagues note that about 20% of women with histories of psychiatric illness experience suicidal ideation during the postpartum period. Ruta Nonacs, MD PhD Parental Adverse Childhood Experiences and ...Read more